Paul J. Boekema
Eindhoven, NB, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
Journal: Digestive diseases and sciences
Published: December 08, 2023
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study.
Journal: European journal of drug metabolism and pharmacokinetics
Published: May 22, 2023
The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
Journal: Inflammatory bowel diseases
Published: March 10, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
Journal: Journal of Crohn's & colitis
Published: February 06, 2023
Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.
Journal: Journal of Crohn's & colitis
Published: January 26, 2023
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.
Journal: Journal of Crohn's & colitis
Published: December 15, 2022
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
Journal: The lancet. Gastroenterology & hepatology
Published: November 02, 2022
Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial.
Journal: BMJ open
Published: May 05, 2021
Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
Journal: Therapeutic drug monitoring
Published: December 01, 2020
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.
Journal: Journal of Crohn's & colitis
Published: October 20, 2020
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
Journal: Alimentary pharmacology & therapeutics
Published: July 19, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026